COMPANY PROFILE

Pearl Diagnostics

Explore full profile

Focused on development and commercialization of products to enable early detection and prevention of fungal infections

Baltimore, United StatesFounded 2014Biotech & Life Sciences

Valuation $50–100M Last recorded · 2026

Headcount <100 Current team size

Total funding $10–50M Disclosed equity funding

Unlock exact values

About Pearl Diagnostics

PearlDx specializes in the development and commercialization of diagnostic products aimed at the early detection and prevention of fungal infections. The company primarily serves patients who are at high risk of fungal infections, such as those undergoing organ transplantation, cancer therapy, or immunosuppressive treatments. Operating within the healthcare diagnostics market, PearlDx's business model focuses on creating and selling diagnostic tests that can identify fungal infections before they become severe, thereby improving patient outcomes and reducing healthcare costs. The company generates revenue through the sale of its diagnostic products, including its flagship urine test for detecting fungal infections in the lungs. PearlDx is based in the Johns Hopkins Fast Forward Accelerator in Baltimore, Maryland, and is a certified Women Owned Small Business by the U.S. Small Business Administration. The company has been active since 2014 and has received multiple patents for its innovative diagnostic technologies.

MoreLess Source: Dealroom company data

At a glance

Status: Operational
Founded: 2014
Headquarters: Baltimore, United States
Employees: 6
Open positions: None listed
Dealroom signal: 58.9/100
Industry: Health
Sub-industry: BioTechnology
Sector: Biotech & Life Sciences, Biotechnology, Spinout, Biotech and Pharma, DT and LS, science-based
Business model: Manufacturing
Client focus: b2b
Links: Website LinkedIn

Knowledge graph

Founder mafia, market maps, research and news connected to this company by Dealroom

Funding history

3 recorded events

Company financing events and reported valuations.

Deal type	Date	Amount	Valuation	Investors	Source
SERIES A✓Equity / VC	Mar 2026	$11M	$45M	Undisclosed	↗
SEED✓Equity / VC	Jul 2022	$3.5M	$14M	Undisclosed	↗

Showing the latest 2 of 3 recorded eventsBook a demo for the full funding history →

Growth signals

Pearl Diagnostics website traffic

Latest recorded traffic for Pearl Diagnostics is 1.7K monthly website visits, down 15% over the last three months. Pearl Diagnostics's team declined 14.3% over the past year.

Latest monthly visits1.7K 3-month web change-15% 1-year team growth-14.3%

Monthly website visitsDec 2022–Jul 2026

Explore monthly traffic historyTrack growth over time and compare with peersBook a demo

Summary metrics are public; monthly history is available with a demoCompare with peers →

Similar companies

Closest operating peers by Dealroom taxonomy

Company identity and context are open; selected comparison metrics preview what is available on the platform.

Company	Headquarters	Status	Employees	Total funding	Valuation
BTBrink TherapeuticsUnlocking in vivo cell therapy with the next generation of gene editing technology	Saint-Mandé, France	Operational	12	$3.9M	$15M
ETEvolving TherapeuticsPhage-based solutions to combat bacteria	Paterna, Spain	Operational
ATAer TherapeuticsClinical-stage biopharmaceutical company developing inhaled treatments for muco-obstructive lung diseases	San Francisco, United States	Operational
INInnoSkelA pioneering biotechnology company developing therapies for rare skeletal diseases	Valbonne, France	Operational
4P4P Pharma4P-Pharma \| Translating Science to Product	Lille, France	Operational
IGIgyxosInnovative pharmaceutical products for human reproductive health	Nouzilly, France	Operational
ACActipulseActipulse International specializes in the diagnostic and treatment of neurological and psychiatric pathologies	Cambridge, United States	Operational
DIDiamanteA national company that specializes in cleaning and maintenance services	Verona, Italy	Operational